Trials / Completed
CompletedNCT02634346
A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)
A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects With Acute Exacerbation of Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 403 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy of ALKS 3831 in adult subjects with acute exacerbation of schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALK3831 | Daily dosing |
| DRUG | Olanzapine | Daily dosing |
| DRUG | Placebo | Daily dosing |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2017-05-25
- Completion
- 2017-06-07
- First posted
- 2015-12-18
- Last updated
- 2018-06-27
- Results posted
- 2018-06-27
Locations
31 sites across 4 countries: United States, Bulgaria, Serbia, Ukraine
Source: ClinicalTrials.gov record NCT02634346. Inclusion in this directory is not an endorsement.